Invesco Biotechnology & Genome ETF PBE

Medalist Rating as of | See Invesco Investment Hub

Morningstar’s Analysis PBE

Will PBE outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PBE

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 45.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Vertex Pharmaceuticals Inc

4.98 14M
Healthcare

Amgen Inc

4.94 14M
Healthcare

Royalty Pharma PLC Class A

4.85 14M
Healthcare

Biogen Inc

4.83 14M
Healthcare

Regeneron Pharmaceuticals Inc

4.78 14M
Healthcare

CareDx Inc

4.56 13M
Healthcare

Gilead Sciences Inc

4.55 13M
Healthcare

Alnylam Pharmaceuticals Inc

4.28 12M
Healthcare

United Therapeutics Corp

4.08 12M
Healthcare

Bio-Techne Corp

3.64 10M
Healthcare

Sponsor Center